

The Influence of the Amino Acid Transporter LAT1 on Patient Prognosis and the Relationships between Tumor Immunometabolic and Proliferative Features Depend on Menopausal Status in Breast Cancer

Gautham Ramshankar^{1,2}, Ryan Liu^{2,3}, and Rachel J. Perry^{2*}

¹Irvington High School, Fremont, CA

²Departments of Cellular & Molecular Physiology and Internal Medicine (Endocrinology), Yale School of Medicine, New Haven, CT

³Cedar Park High School, Cedar Park, TX

*Correspondence to: rachel.perry@yale.edu

Abstract

L-type Amino Acid Transporter 1 (LAT1) facilitates the uptake of specific essential amino acids, and due to this quality, it has been correlated to worse patient outcomes in various cancer types. However, the relationship between LAT1 and various clinical factors, including menopausal status, in mediating LAT1's prognostic effects remains incompletely understood. This is particularly true in the unique subset of tumors that are both obesity-associated and responsive to immunotherapy, including breast cancer. To close this gap, we employed 6 sets of transcriptomic data using the Kaplan-Meier model in the Xena Functional Genomics Explorer, demonstrating that higher LAT1 expression diminishes breast cancer patients' survival probability. Additionally, we analyzed 3'-Deoxy-3'-¹⁸F-Fluorothymidine positron emission tomography-computed tomography (¹⁸F-FLT PET-CT) images found on The Cancer Imaging Archive (TCIA). After separating all patients based on menopausal status, we correlated the measured ¹⁸F-FLT uptake with various clinical parameters quantifying body composition, tumor proliferation, and immune cell infiltration. By analyzing a wealth of deidentified, open-access data, the current study investigates the impact of LAT1 expression on breast cancer prognosis, along with the menopausal status-dependent associations between tumor proliferation, immunometabolism, and systemic metabolism.

Introduction

As the second leading cause of cancer deaths in women, breast cancer has become a major clinical and social burden, with annual out-of-pocket costs for breast cancer care in the U.S. exceeding \$3 billion in 2019 [1]. Because breast cancer has high economic and social costs, it has become increasingly necessary to identify potential risk factors, biomarkers, and treatments. Nearly 30% of breast cancer deaths are caused by modifiable risk factors like excess body

38 weight and alcohol consumption [2]. Several of the modifiable risk factors that predispose to
39 breast cancer converge on metabolism. Consequently, a key priority in the cancer field has been
40 to investigate tumor metabolism and how it can be affected by a patient's lifestyle. In the 1920s,
41 Otto Warburg discovered that in order to sustain their energetic needs while prioritizing
42 generating the biomass and nucleotides required for rapid proliferation and growth, cancer cells
43 have greater metabolic demands than their benign counterparts. Because of this, oncogenic
44 metabolism is characterized by heightened glycolytic metabolism, which necessitates greater
45 uptake of glucose. This phenomenon is now called the Warburg Effect and has greatly shaped
46 the field of tumor metabolism [3]. However, many years after Warburg's groundbreaking work
47 identifying glucose metabolism as a key contributor to tumor pathogenesis, there remains
48 relatively less investigation into the role of amino acid metabolism in tumor progression. The
49 same can be said about amino acid metabolic reprogramming, the abnormal changes to amino
50 acid uptake or metabolic pathways caused by tumor progression. However, past literature has
51 shown that low concentrations of amino acids in the tumor microenvironment inhibit nearby
52 immune cells, weakening immune responses to tumor cells and contributing to tumor
53 progression [4,5]. These data beg further investigation of the tumor- and/or immune cell-centric
54 metabolic role of amino acids in the tumor microenvironment.

55
56 In order to leave the tumor interstitial compartment and undergo metabolism by tumor cells,
57 amino acids must cross the plasma membrane with the help of amino acid transporters. Amino
58 acid transporters can thus facilitate the uptake of amino acids to meet the metabolic needs of
59 cancer cells, explaining why the expression of these transporters has been associated with the
60 proliferation of cancer cells. One such transporter, L-type amino acid transporter 1 (LAT1) is
61 particularly important in the amino acid transport process [4]. Encoded by the gene Solute
62 Carrier Family 7 Member 5 (*SLC7A5*), LAT1 is a light-chain protein that heterodimerizes with
63 its heavy-chain partner 4F2hc (*SLC3A2*) through a conserved disulfide bridge, forming the
64 human LAT1-4F2hc complex. A sodium-independent transporter, LAT1 is an integral membrane
65 protein that mediates the transport of large neutral amino acids like methionine, leucine, and
66 histidine by exchanging them with intracellular glutamine [6]. LAT1 is unique in that it
67 transports multiple essential amino acids, which cannot be synthesized by the human body and
68 must be obtained through diet [7,8]. Considering the dietary dependence of its transported
69 molecules, LAT1 is a particularly intriguing target to participate in the links between lifestyle,
70 systemic metabolism, and cancer.

71
72 Positron emission tomography-computed tomography (PET-CT) is a powerful tool in cancer
73 metabolism research due to its ability to visualize thin slices of tissue in vivo and quantify cells'
74 metabolic activity by measuring radiotracers like 3'-Deoxy-3'-¹⁸F-Fluorothymidine (¹⁸F-FLT).
75 An analog of the nucleoside thymidine, ¹⁸F-FLT is phosphorylated by the cytosolic enzyme
76 thymidine kinase 1 (TK1) and taken up into the cell. During the S-phase of the cell cycle, TK1 is
77 overexpressed nearly tenfold and ¹⁸F-FLT uptake is at its highest. In this way, concentrations of

78 ^{18}F -FLT and TK1 are elevated in cancer cells, making ^{18}F -FLT uptake a quantitative marker for
79 tumor proliferation [9–12]. Ki-67 is a nuclear nonhistone protein, and because it is only
80 expressed in cells that are not in the G_0 phase of the cell cycle, it can only be observed in
81 actively-proliferating cells. This quality has made Ki-67 a classic proliferative marker for tumor
82 cells [13], and is included in the datasets analyzed in the current report.

83
84 Past studies have demonstrated that menopausal status affects to what extent obesity is a risk
85 factor for developing breast cancer. In multiple studies, obesity has been observed to have a
86 protective relationship with breast cancer risk in premenopausal patients whereas it is a risk
87 factor for breast cancer in postmenopausal patients [14]. Because of this, we segmented our
88 analyses based on patients' menopausal statuses. We used body mass index (BMI) in kg/m^2 as a
89 metric for obesity. By analyzing PET-CT scans of 58 patients from The National Cancer
90 Imaging Archive (TCIA), we correlate patients' calculated ^{18}F -FLT uptake and Ki-67 index
91 values to their BMIs to study the relationship between obesity and breast cancer [10,15,16].

92
93 To demonstrate the relationship between LAT1 and poorer health outcomes with a larger sample
94 size, we leveraged RNA-seq data in the UCSC Xena Functional Genomics Explorer [17]. This
95 allowed us to visualize the effect of LAT1 expression on breast cancer prognosis in
96 premenopausal and postmenopausal patients. Ultimately, we used a similar workflow to our prior
97 published work to examine the impact of SLC7A5, a gene with a drastically different role in
98 metabolism, in breast cancer [18]. Our analyses reveal new insights into the associations between
99 clinical variables (obesity, menopausal status), cell proliferation, infiltration with multiple
100 immune cell subtypes, tumor LAT1 expression, and survival in breast cancer patients, which
101 deepen our understanding of the bidirectional relationships that may inform interventional
102 studies targeting these variables in individuals with breast cancer.

103 104 **Methods**

105 **^{18}F -FLT PET-CT Quantitative Image Analysis**

106 Deidentified PET-CT images produced during the ACRIN 6688 clinical trial [10] were obtained
107 from The Cancer Imaging Archive (TCIA). This dataset, “ACRIN-FLT-Breast (ACRIN 6688)”,
108 can be found here:

109 <https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=30671268>. Because only
110 publicly available, deidentified data were analyzed, separate ethical approval is not required. We
111 analyzed the scans of all patients with a menopausal status, height, weight, and 5 clear CT slices
112 (i.e., slices in which the primary breast tumor could be identified and its corresponding SUV
113 values could be generated) present in the dataset. 58 of the 90 enrolled patients in the ACRIN
114 clinical trial met these criteria, and all were analyzed. Of these 58 patients, 26 were
115 premenopausal and 32 were postmenopausal. Scans taken at 3 different dates were available for
116 most patients, and we used the earliest scan (from the baseline scanning which was defined to be
117 4 weeks before any treatment was administered) to minimize the chemotherapeutic effect of the

118 treatment used in the clinical trial. Likewise, heights and weights measured on patients' first
119 visits were used. These data were selected for analysis because breast cancer treatment often
120 causes some weight gain [19–22], which may obscure differences in BMI that could promote
121 proliferation.

122
123 The patients' images were uploaded to Fiji ImageJ and we used the PET-CT Viewer plugin to
124 view and analyze them. After identifying the primary breast tumor on the PET image, we
125 selected the tumor and used the Brown Fat Volume tool to draw fixed-volume spheres around
126 the interior regions of interest (ROIs) on the CT slice. 5 slices were used from each patient's
127 scan. SUV parameters were set at 2 to 15, and ^{18}F -FLT uptake was calculated in the tumor tissue
128 in the specified ROI. ^{18}F -FLT uptake on PET-CT scans is measured by calculating and recording
129 lean body mass-corrected standardized uptake values (SUV) of which there are 3 types:
130 SUV_{Mean} , SUV_{Max} , and SUV_{Peak} . After positioning a fixed-volume sphere on a tumor, within the
131 ROI, SUV_{Mean} represents the average SUV, SUV_{Max} indicates the maximum SUV, and SUV_{Peak}
132 corresponds to the SUV derived from a localized cluster of voxels with high uptake [10,23]. The
133 primary endpoint of image analysis was BMI (kg/m^2) correlated to the 3 types of tumor SUV
134 (g/mL).

135

136 **LAT1 Prognostic Analysis**

137 Using the UCSC Xena Functional Genomics Browser (<https://xenabrowser.net/>), we accessed the
138 “TCGA Breast Cancer (BRCA) cohort” (found here:

139 [https://xenabrowser.net/datapages/?cohort=TCGA%20Breast%20Cancer%20\(BRCA\)&removeH](https://xenabrowser.net/datapages/?cohort=TCGA%20Breast%20Cancer%20(BRCA)&removeHub=http%3A%2F%2F127.0.0.1%3A7222)
140 [ub=http%3A%2F%2F127.0.0.1%3A7222](https://xenabrowser.net/datapages/?cohort=TCGA%20Breast%20Cancer%20(BRCA)&removeHub=http%3A%2F%2F127.0.0.1%3A7222)) which included 2 datasets. The BRCA cohort had

141 1247 total patients, and all of them had menopausal statuses recorded, which we accessed
142 through the “Phenotypes” dataset:

143 [https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FBRCA_clinicalMatri](https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FBRCA_clinicalMatrix&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxcna.treehouse.gi.ucsc.edu%3A443)
144 [x&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxcna.treehouse.](https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FBRCA_clinicalMatrix&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxcna.treehouse.gi.ucsc.edu%3A443)
145 [gi.ucsc.edu%3A443](https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FBRCA_clinicalMatrix&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxcna.treehouse.gi.ucsc.edu%3A443). 1236 of the 1247 patients had survival data recorded. The “IlluminaHiSeq”

146 dataset was used to study LAT1 expression and it can be found here:

147 [https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FHiSeqV2&host=https](https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FHiSeqV2&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=http%3A%2F%2F127.0.0.1%3A7222)
148 [%3A%2F%2Ftcga.xenahubs.net&removeHub=http%3A%2F%2F127.0.0.1%3A7222](https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FHiSeqV2&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=http%3A%2F%2F127.0.0.1%3A7222). The

149 “IlluminaHiSeq” dataset used fragments per kilobase of exon per million mapped fragments
150 (FPKM) to measure gene expression. Again, only openly available human data were analyzed.

151 1218 of the 1247 patients had LAT1 expression data. These datasets were used alongside the
152 Kaplan-Meier model in the Xena visualization suite to analyze LAT1 and its effect on breast
153 cancer prognosis.

154

155 To analyze LAT1 expression, the following workflow was used: the 1247 patients were added to
156 Column A. SLC7A5 was added to Column B as a genomic variable with the gene expression
157 dataset selected, and menopause status was added to Column C as a phenotypic variable. After

158 removing null and duplicate samples, a Kaplan-Meier (KM) plot was generated in Column B to
159 show LAT1 expression and its effect on prognosis in 1005 of the 1247 patients. Next, low and
160 high-expression groups were created from these patients. After 34 patients with indeterminate
161 menopausal statuses were removed from the dataset, 10.46 FPKM was calculated by Xena to be
162 the median for LAT1 expression. Patients were divided at the median: 485 patients were in the
163 low expression group (< 10.46 FPKM), and 486 patients were in the high expression group (>=
164 10.46 FPKM). A KM plot was generated for each group using Column C, creating 2 KM plots
165 with the premenopausal, perimenopausal, and postmenopausal patients in each expression group.

166
167 In addition to the BRCA dataset, the following datasets were used to access breast cancer
168 patients' gene expression data: "RSEM norm-count" from the "TCGA TARGET GTEx" cohort
169 (https://xenabrowser.net/datapages/?dataset=TcgaTargetGtex_RSEM_Hugo_norm_count&host=https%3A%2F%2Ftoil.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443), "Desmedt 76 Gene Node-Neg Gene Exp" from the "node-negative breast cancer
172 (Desmedt 2007)" cohort
173 (https://xenabrowser.net/datapages/?dataset=desmedt2007_public%2Fdesmedt2007_genomicMatrix&host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443), "gene expression RNAseq - US projects" from the "ICGC (donor
176 centric)" cohort
177 (https://xenabrowser.net/datapages/?dataset=donor%2Fexp_seq.all_projects.donor.USonly.xena.tsv&host=https%3A%2F%2Ficgc.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443), "Gene Expression" from the "Breast Cancer (Chin 2006)" cohort
180 (https://xenabrowser.net/datapages/?dataset=chin2006_public%2Fchin2006Exp_genomicMatrix&host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443), and "Miller TP53 Gene Exp" from the "Breast Cancer (Miller 2005)"
183 cohort
184 (https://xenabrowser.net/datapages/?dataset=miller2005_public%2Fmiller2005_genomicMatrix&host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443). To measure expression, the "TCGA TARGET GTEx" dataset used
187 FPKM, the "ICGC (donor centric)" dataset used normalized read count, and the "Node-negative
188 breast cancer (Desmedt 2007)" and "Breast Cancer (Miller 2005)" datasets used log₂ units.
189 Although these gene expression datasets did not include menopausal status as a possible
190 phenotypic variable, our selection criteria were to include breast cancer datasets that had RNA-
191 seq data on SLC7A5 and survival data from the same patients that could be used to produce
192 Kaplan-Meier plots on the Xena platform. Each dataset was used in the same way: SLC7A5 was
193 selected as a genomic variable in Column B, and after null and duplicate samples were removed,
194 a KM plot was generated. For the "TCGA TARGET GTEx" and "ICGC (donor centric)"
195 datasets, only patients with breast tumors were selected for the analysis.

196

197 All of the KM plots were created with Overall Survival as the dependent variable unless
198 otherwise specified. After patients were split at the median for the gene expression analyses,
199 some groups had an unequal number of patients because patients with the same expression levels
200 were put in the same group. Some patients were at the expression median, and the median was
201 calculated to ensure they were placed in the high-expression group while keeping the sizes of
202 each expression group roughly the same.

203

204 **Statistical Analysis**

205 Correlation tests were performed between patients' SUV and BMI values. 26 premenopausal
206 patients' BMIs ranged from 23.829 to 142.822 kg/m² (mean [SD] = 33.972 [22.584]), and 32
207 postmenopausal patients' BMIs ranged from 17.940 to 199.219 kg/m² (mean [SD] = 40.865
208 [36.818]). The unusually high BMI values are driven by unusually low heights reported for these
209 patients; however, only one premenopausal and postmenopausal patient had a reported BMI
210 above 100. Because 5 slices were used per patient, each patient had 5 SUV_{Max} values and 5
211 SUV_{Peak} values but only 1 BMI. In order to correlate BMI and SUV, we needed the same number
212 of values for each. In order to get one SUV for each patient, we took the mean of the SUVs
213 produced from all 5 slices. For SUV_{Mean}, the calculated SUV had a margin of error indicated by a
214 plus-minus sign. This meant that the calculation of each SUV_{Mean} yielded 2 numerical values,
215 one being the high value and the other being the low value, so 5 slices yield 10 SUV_{Mean} values
216 per patient. We took the mean of these 10 values for each patient. Each of these individual SUVs
217 was then correlated with each patient's BMI.

218

219 We also correlated each patient's 3 types of SUVs to their Ki-67 values to further inform the
220 validity of ¹⁸F-FLT uptake as a metric for tumor proliferation. BMI was also correlated to Ki-67.
221 All correlations were two-tailed Pearson correlation tests performed after patients' data were
222 segmented by menopausal status. Shapiro-Wilk tests were also performed to determine if any
223 groups of data were normally distributed. Student's t-tests and Mann-Whitney U tests were
224 performed on parametric and nonparametric data, respectively, to assess difference. For both
225 tests, all data were transformed using log₂ fold changes of the mean.

226

227 Unless otherwise specified, statistical analysis was done and graphs were made in Python 3.9
228 using the pandas (version 1.5) and SciPy (version 1.10) libraries. The two-tailed Pearson
229 correlation tests were conducted using the "pearsonr" function from the scipy.stats module. The
230 Mann-Whitney U tests were conducted using the "mannwhitney" function, the Student's t-tests
231 were conducted using the "ttest_ind" function, and the Shapiro-Wilk tests were performed using
232 the "shapiro" function, all from the scipy.stats module. All Python code can be found here:
233 <https://github.com/gramshankar/LAT1BreastCancer>. For each of the KM plots, a log-rank test
234 was conducted by Xena to compare the curves in the graph. Test statistics and p-values were
235 calculated. Statistical significance was indicated by p-values less than 0.05, and marginally

236 significant results have p-values greater than 0.05 but less than 0.10.

237

238 Results

239 Correlation analysis between proliferative markers, obesity, and immune cells by 240 menopausal status

241 In premenopausal patients, Ki-67 insignificantly positively correlated with SUV_{Mean} , SUV_{Peak}
242 (marginal significance), and SUV_{Max} (marginal significance) (Fig 1A). However, the relationship
243 between Ki-67 and tumor ^{18}F -FLT uptake was statistically stronger in postmenopausal patients,
244 in whom Ki-67 significantly positively correlated with SUV_{Mean} , SUV_{Peak} , and SUV_{Max} (Fig 1B).

245

246 In premenopausal patients, BMI insignificantly negatively correlated with SUV_{Mean} , SUV_{Peak} ,
247 and SUV_{Max} (Fig 1A). In postmenopausal patients, BMI insignificantly positively correlated with
248 SUV_{Mean} (marginal significance), SUV_{Peak} , and SUV_{Max} (Fig 1B). In premenopausal and
249 postmenopausal patients, BMI insignificantly positively correlated with Ki-67 (Fig 1A, Fig 1B).

250

251 In premenopausal patients, basophil, eosinophil, neutrophil, monocyte, and lymphocyte counts
252 insignificantly negatively correlated with SUV_{Mean} , SUV_{Peak} , and SUV_{Max} . White blood cell
253 counts insignificantly positively correlated with SUV_{Mean} , SUV_{Peak} , and SUV_{Max} . All immune
254 cells insignificantly negatively correlated with Ki-67 (Fig 1A).

255

256 In postmenopausal patients, basophil, eosinophil, monocyte, white blood cell, and lymphocyte
257 counts insignificantly positively correlated with SUV_{Mean} , SUV_{Peak} , and SUV_{Max} . Neutrophil
258 counts insignificantly negatively correlated with SUV_{Mean} , SUV_{Peak} , and SUV_{Max} . Basophil,
259 eosinophil, monocyte, and lymphocyte counts insignificantly negatively correlated with Ki-67.
260 Neutrophil and white blood cell counts insignificantly positively correlated with Ki-67 (Fig 1B).


261

262 In premenopausal patients, BMI negatively correlated with basophil, eosinophil, monocyte, and
263 lymphocyte counts and positively correlated with neutrophil and white blood cell counts (Fig
264 1A). Opposite relationships were observed in postmenopausal patients, in whom BMI positively
265 correlated with basophil, eosinophil, monocyte, and lymphocyte counts and negatively correlated
266 with neutrophil and white blood cell counts (Fig 1B).

267

268 These correlation tests' p-values are presented in Tables 1 - 4. In addition, the results from the
269 Mann-Whitney and Student's t-tests performed are presented in Tables 5 - 8.

270



271
 272 **Fig 1. Correlations between clinical variables.** Proliferative markers (Ki-67 and lean body
 273 mass-corrected ^{18}F -FLT uptake measured by SUV_{Mean} , SUV_{Peak} , and SUV_{Max}), obesity (BMI),
 274 and immune cell counts (basophil, eosinophil, neutrophil, monocyte, white blood cell, and
 275 lymphocyte) were correlated in (A) premenopausal and (B) postmenopausal patients. Pearson r
 276 values were calculated and correlation matrices were generated in GraphPad Prism version 9.5.1.
 277
 278

	Premenopausal Patients	Postmenopausal Patients
SUV_{Mean}	0.114	0.035
SUV_{Peak}	<i>0.081</i>	0.045
SUV_{Max}	<i>0.078</i>	0.029

Table 1. P-values from correlations between Ki-67 and ^{18}F -FLT uptake. Significant results are bolded and marginally significant results are bolded and italicized.

	Premenopausal Patients	Postmenopausal Patients
SUV _{Mean}	0.279	<i>0.095</i>
SUV _{Peak}	0.335	0.342
SUV _{Max}	0.268	0.437
Ki-67	0.767	0.691

Table 2. P-values from correlations between BMI and proliferative markers. Marginally significant results are bolded and italicized.

281

	Basophils	Eosinophils	Neutrophils	Monocytes	WBC	Lymphocyte
SUV _{Mean}	0.395	0.539	0.334	0.190	0.170	0.472
SUV _{Peak}	0.401	0.620	0.420	0.262	0.326	0.404
SUV _{Max}	0.519	0.691	0.520	0.342	0.408	0.537
Ki-67	0.394	0.712	0.626	0.417	0.769	0.132

Table 3. P-values from correlations between immune cells and proliferative markers in premenopausal patients.

282

	Basophils	Eosinophils	Neutrophils	Monocytes	WBC	Lymphocyte
SUV _{Mean}	0.239	0.237	0.671	0.235	0.927	0.233
SUV _{Peak}	0.560	0.563	0.586	0.560	0.913	0.561
SUV _{Max}	0.682	0.685	0.741	0.679	0.946	0.681
Ki-67	0.781	0.737	0.986	0.723	0.783	0.762

Table 4. P-values from correlations between immune cells and proliferative markers in postmenopausal patients.

283

	Premenopausal Patients	Postmenopausal Patients
SUV _{Mean}	0.959	0.291
SUV _{Peak}	0.926	0.528
SUV _{Max}	0.992	0.436

Table 5. Mann-Whitney U tests identify no significant differences between the log2 fold change in Ki-67 and ¹⁸F-FLT uptake in pre- or postmenopausal patients. P-values are shown.

284

	Premenopausal Patients		Postmenopausal Patients	
	Test Statistic	P-value	Test Statistic	P-value
SUV _{Mean}	357	0.735	722	0.004
SUV _{Peak}	277	0.268	618	0.157
SUV _{Max}	295	0.437	614	0.173
Ki-67	226	0.205	393	0.993

Table 6. Mann-Whitney U tests identify differences between the log2 fold change in BMI and SUV_{Mean} in postmenopausal patients, but no other proliferative markers differed in pre- or postmenopausal patients.

285

	Basophils	Eosinophils	Neutrophils	Monocytes	White Blood Cells	Lymphocytes
SUV _{Mean}	0.339	0.619	0.213	0.184	0.803	0.115
SUV _{Peak}	0.339	0.803	0.319	0.229	0.431	0.147
SUV _{Max}	0.318	0.803	0.431	0.340	0.481	0.171
Ki-67	0.755 ^a	0.901	0.135	0.584 ^a	0.142 ^a	0.245

Table 7. Mann-Whitney U and Student’s t-tests identify differences between Immune Cells and Proliferative Markers in Premenopausal Patients. The log₂ fold change of each parameter was compared. The comparisons’ p-values are shown above. Shapiro-Wilk tests were used to assess the data’s normality. Based on these results, normally distributed data were compared using the Student’s t-test, and all other analyses used the Mann-Whitney test.

^a These comparisons use the Student’s t-test.

286

	Basophils	Eosinophils	Neutrophils	Monocytes	White Blood Cells	Lymphocytes
SUV Mean	<0.001	<0.001	0.235	<0.001	0.792	<0.001
SUV _P eak	<0.001	<0.001	0.187	<0.001	0.345	<0.001
SUV Max	<0.001	<0.001	0.124	<0.001	0.244	<0.001
Ki-67	0.010	<0.001	<i>0.091</i>	0.002	0.379	<0.001


Table 8. Mann-Whitney U tests identify differences between immune cells and proliferative markers in postmenopausal patients. The log₂ fold change of each parameter was compared. The comparisons’ p-values are shown above. Significant results are bolded, and marginally significant results are bolded and italicized.

287

288 **LAT1 Expression and Survival Probability**


289 In the TCGA BRCA gene expression dataset, patients in the high LAT1 expression group
 290 experienced lower overall survival than patients in the low expression group until 4000 days
 291 after initial treatment. From that point until 6500 days and again from 6600 days until 7500 days,
 292 the low LAT1 expression group had a worse overall survival rate (Fig 2A). Similarly, patients
 293 with high LAT1 expression had a lower disease-specific survival rate than patients with low
 294 LAT1 expression until 4400 days; after that point until the end of the study, patients in the low
 295 expression group had a lower disease-specific survival rate (Fig 2B).

296



297
 298 **Fig 2. LAT1 expression and prognosis in TCGA BRCA patients.** Prognosis in patients from the
 299 TCGA BRCA gene expression dataset. Patients were separated into high (≥ 10.47 FPKM) and low ($<$
 300 10.47 FPKM) LAT1 expression groups, and (A) overall survival and (B) disease-specific survival were
 301 observed up to 8605 days after initial treatment. The median for expression level is slightly different from
 302 the median stated earlier because patients with indeterminate menopausal status were included in this
 303 analysis.

304
 305 In the “TCGA TARGET GTEx” gene expression dataset, patients in the high LAT1 expression
 306 group (≥ 10.65 FPKM) experienced lower survival rates than the low LAT1 expression group
 307 (< 10.65 FPKM) until 4000 days after initial treatment. From 4000 days until the end of the
 308 study, the low-expression group had a lower survival rate (Fig 3A). In the “Node-negative breast
 309 cancer (Desmedt 2007)” gene expression dataset, after the first 500 days, the high LAT1
 310 expression group ($\geq 0.1221 \log_2$) experienced a lower survival rate than the low LAT1
 311 expression group ($< 0.1221 \log_2$) for the remainder of the study (Fig 3B). In the “ICGC (donor
 312 centric)” gene expression dataset, the high LAT1 expression group (≥ 0.00002400) had lower
 313 survival than the low LAT1 expression group (< 0.00002400) for the entire study. The high
 314 expression group’s survival probability reached 0% near 4000 days (Fig 3C). In the “Breast
 315 Cancer (Chin 2006)” gene expression dataset, except from 1.2 to 1.4 years, the high LAT1
 316 expression group experienced a lower survival rate than the low LAT1 expression group. Units
 317 were not given for this study but it most likely used \log_2 units (Fig 3D). In the “Breast Cancer
 318 (Miller 2005)” gene expression dataset, overall survival data were not available so disease-
 319 specific survival was observed. The high LAT1 expression group ($\geq -0.1707 \log_2$) experienced
 320 worse survival than the low LAT1 expression group ($< -0.1707 \log_2$) for the entire study (Fig
 321 3E). Overall, 2 of the gene expression datasets showed that low LAT1 expression conferred a
 322 poorer prognosis in breast cancer patients than high LAT expression, while 4 others showed the
 323 opposite.
 324




325
 326 **Fig 3. LAT1 expression and prognosis in patients from other datasets.** After patients were separated
 327 into high and low LAT1 expression groups, survival was observed in patients from the (A) “TCGA
 328 TARGET GTEx”, (B) “Node-negative breast cancer (Desmedt 2007)”, (C) “ICGC (donor centric)”, (D)
 329 “Breast Cancer (Chin 2006)”, and (E) “Breast Cancer (Miller 2005)” cohorts.

330
 331 **Survival probability with high LAT1 expression TCGA BRCA patients by menopausal**
 332 **status**

333 The impact of menopausal status on survival in patients with high LAT1 expression is shown in
 334 Fig 4. After 1000 days, postmenopausal patients had the lowest survival rates. Premenopausal
 335 patients had the highest survival rates among the 3 groups until approximately 2500 days, from


336 which point peri-menopausal patients had the highest survival until 3600 days (Fig 4); however,
 337 our ability to draw conclusions regarding survival in peri-menopausal patients is limited by the
 338 relatively low number of patients in this group.
 339



340
 341 **Fig 4. High expression and prognosis in TCGA BRCA patients.** Prognosis in the high expression
 342 group (≥ 10.46 FPKM) from the TCGA BRCA gene expression dataset. The high expression group was
 343 separated into 3 groups: premenopausal, postmenopausal, and peri-menopausal breast cancer patients.
 344

345 **Survival probability with low LAT1 expression TCGA BRCA patients by menopausal**
 346 **status**

347 The impact of menopausal status on survival in patients with low LAT1 expression is shown in
 348 Fig 5. Premenopausal patients had a higher survival rate than postmenopausal patients until 3200
 349 days. Postmenopausal patients, after 3200 days and until the end of the available survival data
 350 for premenopausal patients at approximately 3800 days, exhibited a higher survival rate
 351 compared to premenopausal patients. The few peri-menopausal patients in this study maintained
 352 a 100% survival probability throughout the duration that they were monitored.
 353




354
 355 **Fig 5. Low expression and prognosis in TCGA BRCA patients.** Prognosis in the low expression group
 356 (< 10.46 FPKM) from the TCGA BRCA gene expression dataset. The low expression group was
 357 separated into 3 groups: premenopausal, postmenopausal, and peri-menopausal breast cancer patients.
 358

359

360 **Discussion**

361 Increasing interest in the relationship between systemic metabolism, tumor metabolism,
 362 immunometabolism, and cancer outcomes, alongside evolving technologies expanding both the
 363 available data and the community's ability to mine it to develop new insights. To that end, in this
 364 study, we utilized multiple publicly available breast cancer datasets, including "ACRIN-FLT-
 365 Breast (ACRIN 6688)", TCGA BRCA "Phenotypes", TCGA BRCA "IlluminaHiSeq", "TCGA
 366 TARGET GTEx", "Node-negative breast cancer (Desmedt 2007)", "ICGC (donor centric)",
 367 "Breast Cancer (Chin 2006)", and "Breast Cancer (Miller 2005)", aiming to better understand the
 368 intersection between parameters of systemic metabolic health, tumor gene expression, and
 369 immune cell infiltration, and outcomes in individuals with breast cancer (Fig 6).



370
371 **Fig 6. Summary of factors correlated in this analysis.** Figure created with BioRender.com.
372

373 As opposed to genes or metabolic fluxes involved in glucose [24–31] or lipid metabolism [31–
374 39], there exists a relative paucity of studies exploring the impact of expression of genes
375 regulating amino acid uptake in breast cancer. Therefore, we elected to focus the current study
376 on the expression of LAT1, which transports large amino acids including leucine, isoleucine,
377 valine, phenylalanine, methionine, tyrosine, histidine, and tryptophan into the cell, and its
378 relationships with body weight, tumor cell proliferation, and immune infiltration. Prior literature
379 indicates that LAT1 is involved in protein synthesis [40,41] and mTORC1 activity [42,43], and
380 may also modulate the anti-tumor immune response [44–47]. Overexpression of LAT1 has been
381 observed in a plethora of tumor types ranging from lung to endometrial to liver, but fewer studies
382 of the relationship between LAT1 and breast cancer exist [48]. Furthermore, LAT1 has been less
383 frequently associated with a poor long-term clinical prognosis in breast cancer than in other
384 cancers. Our data, too, provide mixed evidence: while some datasets showed that high LAT1
385 expression was worse for prognosis, others showed the opposite. Namely, the BRCA dataset
386 showed that low LAT1 expression conferred worse survival at some points. This is likely
387 because when compared to the high-expression group, a greater proportion of low-expression
388 patients in the BRCA dataset had a positive margin status. Also, a greater percentage of the low-
389 expression group had a distant metastasis present. The fact that the low LAT1 expression group
390 tended to have more positive margin status and distant metastases than patients in the high-
391 expression group may contribute to the discrepancy between our data on the predictive value of
392 LAT1 versus others, as these have shown to be poor prognostic factors in breast cancer [49,50].
393 Additionally, in the “TCGA TARGET GTEx” dataset, the low-expression group also had lower
394 survival than the high-expression group. Margin status and the presence of distant metastases
395 could also be confounding variables in this dataset, but data were not available to determine that.
396 In this way, we show that the relationship between LAT1 expression and survival in breast
397 cancer patients may be more complicated than previously appreciated.

398

399 Past analyses on LAT1 are not stratified by menopausal status, another unique quality of our
400 study. In breast cancer patients with high tumor LAT1 expression, we observed worse survival in
401 postmenopausal individuals as compared to peri- or premenopausal, but interestingly, these
402 relationships were not observed in patients with low LAT1 expression. This discrepancy may
403 reflect the fact that LAT1 has been shown to be estrogen-dependent in endocrine-responsive
404 cells [51,52]. Therefore, it is likely that more of the tumors in the low LAT1 group were triple-
405 negative breast cancers, which generally have a poor prognosis independently of menopausal
406 status. We recognize that worse survival is expected over the more than 10-year duration of
407 follow-up in the datasets analyzed in postmenopausal patients, who are older and at greater risk
408 for numerous conditions than their younger counterparts. Thus, the fact that survival differences
409 were not observed in the LAT1 group implies that a regulator of LAT1 expression - such as
410 estrogen - may obscure expected differences in survival. Additionally, we observed a positive
411 correlation ($r < 0.5$) between BMI and basophil, eosinophil, monocyte, and lymphocyte counts in
412 postmenopausal patients, a finding not seen in premenopausal patients. On the contrary, the
413 opposite was observed in premenopausal patients. Premenopausal patients experience heightened
414 17β -estradiol levels, dampening obesity-induced inflammation, whereas postmenopausal patients
415 (and those with obesity) have higher levels of estrone, stimulating inflammation. The imbalance
416 between estrone and 17β -estradiol levels that occurs after menopause results in the release of
417 cytokines and the recruitment of nearby immune cells, which likely explains this correlation only
418 being observed in postmenopausal patients [53][s1].

419

420 ^{18}F -fluorodeoxyglucose (^{18}F -FDG) has been the traditional radiotracer utilized in cancer
421 research, and it is still used in the majority of tumor radiotracer analyses. Indeed, the Positron
422 Emission Tomography Response Criteria in Solid Tumors (PERCIST) is based on the use of ^{18}F -
423 FDG as the radiotracer [54,55]. However, although high ^{18}F -FDG uptake correlates with poor
424 prognosis in numerous tumor types, including breast cancer [56–61], it is not a direct readout of
425 tumor proliferative activity. For this, it is necessary to utilize a tracer such as ^{18}F -FLT, an analog
426 of thymidine which is phosphorylated by thymidine kinase prior to incorporation into DNA
427 during cell replication. Because our study employs ^{18}F -FLT imaging as a more direct readout of
428 tumor proliferation rather than ^{18}F -FDG, we provide an analysis that has previously been
429 insufficiently explored. We observe differences in the strength of the correlation between Ki-67
430 and ^{18}F -FLT uptake in pre- and postmenopausal patients: in postmenopausal patients, Ki-67
431 significantly positively correlated with ^{18}F -FLT SUV_{Mean} , SUV_{Peak} , and SUV_{Max} , whereas in
432 premenopausal patients, Ki-67 insignificantly positively correlated with ^{18}F -FLT. These data are
433 consistent with prior studies in which the correlation between Ki-67 and ^{18}F -FLT was found to
434 be relatively weak and dependent on clinical variables (pre- or post-treatment timing, hormone
435 receptor status) [62,63]. Surprisingly, BMI barely correlated with either Ki-67 or ^{18}F -FLT, which
436 may mean that obesity is more involved in the appearance - and potentially recurrence - of
437 cancer rather than its progression once a tumor is already established. Further work will be

438 required to better understand the nuanced relationships between these clinical variables.
439 Additionally, it will be important to understand the relationship between LAT1 expression, ¹⁸F-
440 FLT uptake, and clinical variables including BMI and - better yet [64] - adiposity. In fact, to our
441 knowledge, there are no studies correlating LAT1 expression to all 3 types of ¹⁸F-FLT SUVs.
442 We recognize that a limitation of our study is that BMI is not the best metric for obesity. In the
443 datasets analyzed, there were no clinical data including possible alternatives for BMI like
444 visceral adiposity, so we did not have an alternative to relying on BMI. Correlating ¹⁸F-FLT
445 uptake to both gene expression and a broad range of anthropometric indices, including visceral
446 adiposity, will be of great interest in future studies.

447

448 **Conclusion**

449 Through our analyses, we show that although the extent to which this occurs is stratified by
450 menopausal status, LAT1 expression worsens breast cancer prognosis, bolstering the role of
451 amino acid metabolism in tumor energetics, an aspect of the literature that has been
452 underexplored. Using various clinical variables, we correlated tumor proliferation, body
453 composition, and immune cell populations to identify the complex relationships underlying
454 metabolism, immune surveillance, and cancer progression. Future studies should aim to utilize a
455 wider variety of immune cell types and metrics for body composition, while further segmenting
456 patients based on breast cancer subtype, to gain a more comprehensive understanding of the
457 findings we establish here. In addition, we speculate that future studies should target LAT1 or its
458 heavy chain partner 4F2hc to inhibit the LAT1-4F2hc complex, interventions which may
459 plausibly improve patient outcomes.

460

461 **Acknowledgments**

462 The authors are grateful for awards from the Lion Heart Foundation and from the Yale Cancer
463 Center, which supported this research.

464

465

466 **References**

- 467 1. Tangka F, Yabroff R, Jingxuan Z, Mariotto A. The Cost of Cancer | Blogs | CDC. 26 Oct
468 2021 [cited 5 Jul 2023]. Available: [https://blogs.cdc.gov/cancer/2021/10/26/the-cost-of-](https://blogs.cdc.gov/cancer/2021/10/26/the-cost-of-cancer/)
469 [cancer/](https://blogs.cdc.gov/cancer/2021/10/26/the-cost-of-cancer/)
- 470 2. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast
471 Cancer Statistics, 2022. *CA: A Cancer Journal for Clinicians*. 2022;72: 524–541.
472 doi:10.3322/caac.21754
- 473 3. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? *Trends*
474 *Biochem Sci*. 2016;41: 211–218. doi:10.1016/j.tibs.2015.12.001
- 475 4. Wang D, Wan X. Progress in research on the role of amino acid metabolic reprogramming in
476 tumour therapy: A review. *Biomedicine & Pharmacotherapy*. 2022;156: 113923.
477 doi:10.1016/j.biopha.2022.113923
- 478 5. Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells:
479 essential regulators of the effector functions, and promising opportunities to enhance cancer
480 immunotherapy. *J Hematol Oncol*. 2023;16: 59. doi:10.1186/s13045-023-01453-1
- 481 6. Zhao Y, Wang L, Pan J. The role of L-type amino acid transporter 1 in human tumors.
482 *Intractable Rare Dis Res*. 2015;4: 165–169. doi:10.5582/irdr.2015.01024
- 483 7. El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, et al. The amino
484 acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer
485 subtypes and is a key therapeutic target in luminal B tumours. *Breast Cancer Research*.
486 2018;20: 21. doi:10.1186/s13058-018-0946-6
- 487 8. Yan R, Li Y, Müller J, Zhang Y, Singer S, Xia L, et al. Mechanism of substrate transport and
488 inhibition of the human LAT1-4F2hc amino acid transporter. *Cell Discov*. 2021;7: 1–8.
489 doi:10.1038/s41421-021-00247-4
- 490 9. Sanghera B, Wong WL, Sonoda LI, Beynon G, Makris A, Woolf D, et al. FLT PET-CT in
491 evaluation of treatment response. *Indian J Nucl Med*. 2014;29: 65–73. doi:10.4103/0972-
492 3919.130274
- 493 10. Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, et al. A Phase II Study of
494 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast
495 Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. *J Nucl Med*. 2015;56:
496 1681–1689. doi:10.2967/jnumed.115.160663
- 497 11. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in
498 proliferating and M phase-arrested human cells. *Journal of Biological Chemistry*. 1994;269:
499 21249–21254. doi:10.1016/S0021-9258(17)31956-7

- 500 12. PECK M, POLLACK HA, FRIESEN A, MUZI M, SHONER SC, SHANKLAND EG, et al.
501 Applications of PET imaging with the proliferation marker [18F]-FLT. *Q J Nucl Med Mol*
502 *Imaging*. 2015;59: 95–104.
- 503 13. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody
504 reactive with a human nuclear antigen associated with cell proliferation. *Int J Cancer*.
505 1983;31: 13–20. doi:10.1002/ijc.2910310104
- 506 14. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno-Bueno G. Obesity and
507 Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal
508 Status. *Frontiers in Oncology*. 2021;11. Available:
509 <https://www.frontiersin.org/articles/10.3389/fonc.2021.705911>
- 510 15. Kinahan P, Muzi M, Bialecki B, Coombs L. Data from ACRIN-FLT-Breast. The Cancer
511 Imaging Archive; 2017. doi:10.7937/K9/TCIA.2017.OL20ZMXG
- 512 16. Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging
513 Archive (TCIA): Maintaining and Operating a Public Information Repository. *J Digit*
514 *Imaging*. 2013;26: 1045–1057. doi:10.1007/s10278-013-9622-7
- 515 17. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and
516 interpreting cancer genomics data via the Xena platform. *Nat Biotechnol*. 2020;38: 675–678.
517 doi:10.1038/s41587-020-0546-8
- 518 18. Liu R, Ospanova S, Perry RJ. The impact of variance in carnitine palmitoyltransferase-1
519 expression on breast cancer prognosis is stratified by clinical and anthropometric factors.
520 *PLOS ONE*. 2023;18: e0281252. doi:10.1371/journal.pone.0281252
- 521 19. Levine EG, Raczynski JM, Carpenter JT. Weight gain with breast cancer adjuvant treatment.
522 *Cancer*. 1991;67: 1954–1959. doi:10.1002/1097-0142(19910401)67:7<1954::AID-
523 *CNCR2820670722*>3.0.CO;2-Z
- 524 20. Uhelski A-CR, Blackford AL, Sheng JY, Snyder C, Lehman J, Visvanathan K, et al. Factors
525 associated with weight gain in pre- and post-menopausal women receiving adjuvant
526 endocrine therapy for breast cancer. *J Cancer Surviv*. 2023 [cited 5 Jul 2023].
527 doi:10.1007/s11764-023-01408-y
- 528 21. Walker J, Joy AA, Vos LJ, Stenson TH, Mackey JR, Jovel J, et al. Chemotherapy-induced
529 weight gain in early-stage breast cancer: a prospective matched cohort study reveals
530 associations with inflammation and gut dysbiosis. *BMC Medicine*. 2023;21: 178.
531 doi:10.1186/s12916-023-02751-8
- 532 22. Ee C, Cave A, Vaddiparthi V, Naidoo D, Boyages J. Factors associated with weight gain
533 after breast cancer: Results from a community-based survey of Australian women. *The*
534 *Breast*. 2023;69: 491–498. doi:10.1016/j.breast.2023.01.012

- 535 23. Könik A, O'Donoghue JA, Wahl RL, Graham MM, Van den Abbeele AD. Theranostics: The
536 Role of Quantitative Nuclear Medicine Imaging. *Seminars in Radiation Oncology*. 2021;31:
537 28–36. doi:10.1016/j.semradonc.2020.07.003
- 538 24. Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS. ¹³C High-
539 resolution-magic angle spinning MRS reveals differences in glucose metabolism between
540 two breast cancer xenograft models with different gene expression patterns. *NMR in*
541 *Biomedicine*. 2011;24: 1243–1252. doi:10.1002/nbm.1683
- 542 25. Bawab AQA, Zihlif M, Jarrar Y, Sharab A. Continuous Hypoxia and Glucose Metabolism:
543 The Effects on Gene Expression in MCF7 Breast Cancer Cell Line. *Endocrine, Metabolic &*
544 *Immune Disorders - Drug Targets*. 21: 511–519.
- 545 26. Cheng X, Jia X, Wang C, Zhou S, Chen J, Chen L, et al. Hyperglycemia induces PFKFB3
546 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK
547 activation. *World Journal of Surgical Oncology*. 2023;21: 112. doi:10.1186/s12957-023-
548 02990-2
- 549 27. Jekabsons MB, Merrell M, Skubiz AG, Thornton N, Milasta S, Green D, et al. Breast cancer
550 cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at
551 greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells. *Cancer*
552 *& Metabolism*. 2023;11: 4. doi:10.1186/s40170-023-00303-5
- 553 28. Tucker JD, Doddapaneni R, Lu PJ, Lu QL. Ribitol alters multiple metabolic pathways of
554 central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics
555 profiling of breast cancer. *PLOS ONE*. 2022;17: e0278711.
556 doi:10.1371/journal.pone.0278711
- 557 29. Zhu P, Liu G, Wang X, Lu J, Zhou Y, Chen S, et al. Transcription factor c-Jun modulates
558 GLUT1 in glycolysis and breast cancer metastasis. *BMC Cancer*. 2022;22: 1283.
559 doi:10.1186/s12885-022-10393-x
- 560 30. Ambrosio MR, Mosca G, Migliaccio T, Liguoro D, Nele G, Schonauer F, et al. Glucose
561 Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal
562 Stromal/Stem Cells on Breast Cancer Cell Lines. *Cancers (Basel)*. 2022;14: 5421.
563 doi:10.3390/cancers14215421
- 564 31. Lee R, Lee H-B, Paeng JC, Choi H, Whi W, Han W, et al. Association of androgen receptor
565 expression with glucose metabolic features in triple-negative breast cancer. *PLOS ONE*.
566 2022;17: e0275279. doi:10.1371/journal.pone.0275279
- 567 32. Monaco ME. ACSL4: biomarker, mediator and target in quadruple negative breast cancer.
568 *Oncotarget*. 2023;14: 563–575. doi:10.18632/oncotarget.28453
- 569 33. Tang L, Lei X, Hu H, Li Z, Zhu H, Zhan W, et al. Investigation of fatty acid metabolism-
570 related genes in breast cancer: Implications for Immunotherapy and clinical significance.
571 *Translational Oncology*. 2023;34: 101700. doi:10.1016/j.tranon.2023.101700

- 572 34. Miyashita M, Bell JSK, Wenric S, Karaesmen E, Rhead B, Kase M, et al. Molecular
573 profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals
574 actionable tumor biology differences between European ancestry and African ancestry
575 patient populations. *Breast Cancer Research*. 2023;25: 58. doi:10.1186/s13058-023-01627-2
- 576 35. Qian L, Liu Y-F, Lu S-M, Yang J-J, Miao H-J, He X, et al. Construction of a fatty acid
577 metabolism-related gene signature for predicting prognosis and immune response in breast
578 cancer. *Front Genet*. 2023;14: 1002157. doi:10.3389/fgene.2023.1002157
- 579 36. Qian Z, Chen L, Liu J, Jiang Y, Zhang Y. The emerging role of PPAR-alpha in breast
580 cancer. *Biomedicine & Pharmacotherapy*. 2023;161: 114420.
581 doi:10.1016/j.biopha.2023.114420
- 582 37. Yousuf U, Sofi S, Makhdoomi A, Mir MA. Identification and analysis of dysregulated fatty
583 acid metabolism genes in breast cancer subtypes. *Med Oncol*. 2022;39: 256.
584 doi:10.1007/s12032-022-01861-2
- 585 38. Chang X, Xing P. Identification of a novel lipid metabolism-related gene signature within
586 the tumour immune microenvironment for breast cancer. *Lipids in Health and Disease*.
587 2022;21: 43. doi:10.1186/s12944-022-01651-9
- 588 39. Pham D-V, Park P-H. Adiponectin triggers breast cancer cell death via fatty acid metabolic
589 reprogramming. *Journal of Experimental & Clinical Cancer Research*. 2022;41: 9.
590 doi:10.1186/s13046-021-02223-y
- 591 40. Collao N, Akohene-Mensah P, Nallabelli J, Binet ER, Askarian A, Lloyd J, et al. The role of
592 L-type amino acid transporter 1 (Slc7a5) during in vitro myogenesis. *American Journal of*
593 *Physiology-Cell Physiology*. 2022;323: C595–C605. doi:10.1152/ajpcell.00162.2021
- 594 41. Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Endou H, et al. Pharmacologic
595 inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and
596 downregulates global translation in cancer cells. *Journal of Cellular and Molecular Medicine*.
597 2022;26: 5246–5256. doi:10.1111/jcmm.17553
- 598 42. Chiduza GN, Johnson RM, Wright GSA, Antonyuk SV, Muench SP, Hasnain SS. LAT1
599 (SLC7A5) and CD98hc (SLC3A2) complex dynamics revealed by single-particle cryo-EM.
600 *Acta Crystallogr D Struct Biol*. 2019;75: 660–669. doi:10.1107/S2059798319009094
- 601 43. Li Y, Wang W, Wu X, Ling S, Ma Y, Huang P. SLC7A5 serves as a prognostic factor of
602 breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling
603 pathway. *Ann Transl Med*. 2021;9: 892. doi:10.21037/atm-21-2247
- 604 44. Solvay M, Holfelder P, Klaessens S, Pilotte L, Stroobant V, Lamy J, et al. Tryptophan
605 depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-
606 mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes. *J*
607 *Immunother Cancer*. 2023;11: e006728. doi:10.1136/jitc-2023-006728

- 608 45. Tian X, Liu X, Ding J, Wang F, Wang K, Liu J, et al. An anti-CD98 antibody displaying pH-
609 dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-
610 humanized mice. *Nat Biomed Eng.* 2023;7: 8–23. doi:10.1038/s41551-022-00956-5
- 611 46. Liu Y-H, Li Y-L, Shen H-T, Chien P-J, Sheu G-T, Wang B-Y, et al. L-Type Amino Acid
612 Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1
613 Ligand 1 in Lung Cancer Cells. *Int J Mol Sci.* 2021;22: 10955. doi:10.3390/ijms222010955
- 614 47. Kuriyama K, Higuchi T, Yokobori T, Saito H, Yoshida T, Hara K, et al. Uptake of positron
615 emission tomography tracers reflects the tumor immune status in esophageal squamous cell
616 carcinoma. *Cancer Sci.* 2020;111: 1969–1978. doi:10.1111/cas.14421
- 617 48. Häfliger P, Charles R-P. The L-Type Amino Acid Transporter LAT1—An Emerging Target
618 in Cancer. *Int J Mol Sci.* 2019;20: 2428. doi:10.3390/ijms20102428
- 619 49. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the
620 risk of distant metastasis at initial diagnosis: a population-based study. *Cancer Manag Res.*
621 2018;10: 5329–5338. doi:10.2147/CMAR.S176763
- 622 50. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczeck B, et al. Margin status
623 and survival outcomes after breast cancer conservation surgery: prospectively registered
624 systematic review and meta-analysis. *BMJ.* 2022;378: e070346. doi:10.1136/bmj-2022-
625 070346
- 626 51. Sevigny CM, Sengupta S, Luo Z, Liu X, Hu R, Zhang Z, et al. SLCs contribute to endocrine
627 resistance in breast cancer: role of SLC7A5 (LAT1). *bioRxiv*; 2019. p. 555342.
628 doi:10.1101/555342
- 629 52. Shennan DB, Thomson J, Gow IF, Travers MT, Barber MC. l-Leucine transport in human
630 breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and
631 molecular identity of the transporter. *Biochimica et Biophysica Acta (BBA) -*
632 *Biomembranes.* 2004;1664: 206–216. doi:10.1016/j.bbamem.2004.05.008
- 633 53. Qureshi R, Picon-Ruiz M, Aurrekoetxea-Rodriguez I, Paiva VN de, D’Amico M, Yoon H, et
634 al. The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven
635 Mammary Inflammation and Breast Cancer Development. *Cell Metabolism.* 2020;31: 1154-
636 1172.e9. doi:10.1016/j.cmet.2020.05.008
- 637 54. Sato M, Harada-Shoji N, Toyohara T, Soga T, Itoh M, Miyashita M, et al. L-type amino acid
638 transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino
639 acid metabolism. *Sci Rep.* 2021;11: 589. doi:10.1038/s41598-020-80668-5
- 640 55. Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, et al. Response to
641 neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in
642 Japan. *Eur J Nucl Med Mol Imaging.* 2018;45: 1661–1671. doi:10.1007/s00259-018-4008-1
- 643 56. Cremoux P de, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, et al. 18 FDG-
644 PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and

- 645 outcome in HER2-negative advanced luminal breast cancers patients. *Oncotarget*. 2018;9:
646 16343–16353. doi:10.18632/oncotarget.24674
- 647 57. Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, et al. 18FDG-
648 PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of
649 clinicopathological parameters and PET image-derived indices including tumor texture
650 analysis. *Breast Cancer Research*. 2017;19: 3. doi:10.1186/s13058-016-0793-2
- 651 58. Humbert O, Riedinger J-M, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V,
652 et al. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of
653 Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Clin Cancer Res*.
654 2015;21: 5460–5468. doi:10.1158/1078-0432.CCR-15-0384
- 655 59. Groheux D, Sanna A, Majdoub M, Cremoux P de, Giacchetti S, Teixeira L, et al. Baseline
656 Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy
657 Are Prognostic of Outcome in ER+/HER2- Breast Cancer. *Journal of Nuclear Medicine*.
658 2015;56: 824–831. doi:10.2967/jnumed.115.154138
- 659 60. Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, et al. The utility of 18
660 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
661 *Cancer Imaging*. 2014;14: 13. doi:10.1186/1470-7330-14-13
- 662 61. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, et al. Monitoring
663 of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality
664 (PET/CT/MRI) imaging in locally advanced breast cancer. *Breast Cancer Res Treat*.
665 2011;128: 119–126. doi:10.1007/s10549-011-1442-1
- 666 62. Romine PE, Peterson LM, Kurland BF, Byrd DW, Novakova-Jiresova A, Muzi M, et al.
667 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early
668 response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a
669 window-of-opportunity study. *Breast Cancer Research*. 2021;23: 88. doi:10.1186/s13058-
670 021-01464-1
- 671 63. Su T-P, Huang J-S, Chang P-H, Lui K-W, Hsieh JC-H, Ng S-H, et al. Prospective
672 comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment
673 response and survival in metastatic breast cancer. *BMC Cancer*. 2021;21: 908.
674 doi:10.1186/s12885-021-08649-z
- 675 64. Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal
676 analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma
677 and adenocarcinoma. *npj Precis Onc*. 2022;6: 1–10. doi:10.1038/s41698-021-00248-2
- 678